<?xml version="1.0" encoding="UTF-8"?>
<p>Several mAbs (fully human or humanized) that target both the S1-RBD and non-RBD as well as S2 domain of CoVs have been generated and tested in cell cultures for virus-neutralizing capability as well as in animal models for prophylactic and post-exposure efficacies.
 <sup>
  <xref rid="CIT0065">65</xref>
 </sup> These antibodies could be useful tools also in the development of vaccines, therapeutic drugs, and antiviral inhibitors.
</p>
